Home › Calculator › ATNM Dividend Calculator 2026
ATNM Dividend DRIP Calculator 2026
194.17% YieldHealthcareActinium Pharmaceuticals, Inc. · AMEX
Price: $1.03 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When ATNM pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your ATNM snowball 📈
$10,000 in ATNM → $45.9K in 10 years · $7.23/month
About Actinium Pharmaceuticals, Inc. (ATNM) — Dividend Analysis 2026
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
Compare ATNM with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full ATNM DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open ATNM position with:
🌍 ATNM Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ATNM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 194.17% | 191.37% | $19,417 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 165.04% | 162.24% | $16,504 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 155.34% | 152.54% | $15,534 / yr |
| 🇬🇧 UK ISA | 0% | 194.17% | 191.37% | $19,417 / yr |
| 🇬🇧 UK Taxable | 8.75% | 177.18% | 174.38% | $17,718 / yr |
| 🇨🇦 TFSA | 0% | 194.17% | 191.37% | $19,417 / yr |
| 🇨🇦 CA Taxable | 25% | 145.63% | 142.83% | $14,563 / yr |
| 🇦🇺 Super (pension) | 15% | 165.04% | 162.24% | $16,504 / yr |
| 🇦🇺 AU Taxable | 30% | 135.92% | 133.12% | $13,592 / yr |
| 🇩🇪 DE Taxable | 26.375% | 142.96% | 140.16% | $14,296 / yr |
| 🇫🇷 FR Taxable | 30% | 135.92% | 133.12% | $13,592 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ATNM Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ATNM Dividend Payment Schedule
ATNM pays quarterly — 4 times per year. Next ex-div: TBD.
📊 ATNM vs Healthcare Benchmarks
How ATNM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ATNM sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ATNM Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-09-02 | 92,400 | $1.00 | $92.4K | ||
| A-Award | 2026-09-02 | 61,600 | — | — | ||
| A-Award | 2026-09-02 | 94,200 | $1.00 | $94.2K | ||
| A-Award | 2026-09-02 | 62,800 | — | — | ||
| A-Award | 2026-09-02 | 27,000 | $1.00 | $27.0K | ||
| A-Award | 2026-09-02 | 18,000 | — | — | ||
| A-Award | 2026-09-02 | 1,027,274 | — | — | ||
| A-Award | 2026-09-02 | 1,130,400 | $1.00 | $1.13M | ||
| A-Award | 2026-09-02 | 753,600 | — | — | ||
| A-Award | 2026-09-02 | 94,200 | $1.00 | $94.2K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ATNM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Actinium Pharmaceuticals, Inc. (ATNM) is currently trading at $1.03, 92% below its 52-week high. The current dividend yield is 194.17% based on an annual payout of $2.00 per share.
ATNM (Actinium Pharmaceuticals, Inc.) — 194.17% Dividend Yield Analysis
Actinium Pharmaceuticals, Inc. (ATNM) is a healthcare stock currently trading at $1.03 with a dividend yield of 194.17%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, ATNM has grown its dividend at a compound annual rate of 50.0%.
- Above-average yield (194.17%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest ATNM News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.